Allersine Eye Drops is a clear,
Each ml contains Tetrahydrozoline HCI 0.5 mg
Benzalkonium Chloride 0.01% w/v
directly stimulates a-adrenergic receptors of the sympathetic nervous system
and exerts little or no effect on b-adrenergic receptors. Following topical
application of tetrahydrozoline to the conjunctiva, small arterioles are
constricted and conjunctival congestion is temporarily relieved, but
reactive hyperaemia may occur. The drug also may produce mydriasis when
applied to the conjunctiva, but this effect is usually minimal with the
concentrations used as ocular decongestants.
Following topical application of Tetrahydrozoline hydrochloride solutions to
the conjunctiva local vasoconstriction usually occurs within a few minutes
and may persist for 4-8 hours. Occasionally, enough tetrahydrozoline may be
absorbed to produce systemic effects. Information on the distribution and
elimination of the drug in humans is not available.
Provides temporary relief from soreness, burning, itching, irritation and
congestion of the eyes in a variety of allergy and eye irritation conditions
caused by allergies, smog, smoke, dust, wind and other eye irritants.
Place one or two drops in the affected eye(s) up to four times daily or as
directed by a physician. Not recommended for use in children under 6 years
of age except on medical advice, To avoid contamination of this product, do
not touch dropper tip to other surfaces and always replace cap after using.
Patients should be cautioned to remove contact lenses before using this
product, and that contact lenses should not be reinserted until after 15
minutes have elapsed after the instillation of the drops.
Contraindicated in patients with a known hypersensitivity to any component
of the product.
Allersine should not be used in the presence of narrow-angle glaucoma and
serious eye infections. If the solution changes colour or becomes cloudy, it
should not be used.
WARNING & PRECAUTIONS
Patents should be warned that if they experience eye pain, changes in
vision, continued redness or irritation of the eye, or if the condition
worsens or persists for more than 72 hours, that they should discontinue use
and consult a doctor, as this may be the sign of a more serious condition.
Overuse of this product may produce increased redness of the eye.
This product should be used with caution in patients with glaucoma, other
serious eye diseases, hyperthyroidism, heart disease, hypertension, or
diabetes melitis, or in those receiving monoamine oxidase inhibitors.
This product should not be substituted for contact lens fluid.
PREGNANCY & LACTATION
Use in pregnancy: Safe use of Tetrahydrozoline HCI during pregnancy has not
Use in lactation: None available.
The incidence of serious adverse effects is low in patients receiving
therapeutic dosages of topical Tetrahydrozoline hydrochloride. Excessive
dosage and/or prolonged or too frequent use may irritate conjunctiva,
especially in children, and cause adverse systemic effects.
Use of Tetrahydrozoline in the eye may cause blurred vision, irritation, and
mydriasis. Conjunctival application of Tetrahydrozoline, especially when
high concentrations are used in geriatric patients, may liberate pigment
granules, presumably from the iris. Prolonged use may worsen symptoms and
should be avoided. In children, excessive dosage of the drug may cause
severe drowsiness accompanied by profuse sweating.
Ophthalmic use of Tetrahydrozoline may occasionally cause systemic
sympathomimetic effects such as headache, hypertension, weakness, sweating,
palpitation, and tremors. Overdosage of the drug may produce CNS depression
with drowsiness, decreased body temperature, bradycardia, shock like
hypotension, apnea, and coma.
SYMPTOMS AND TREATMENT OF
In case of accidental
ingestion, seek professional advice. Symptoms of overdosage may include CNS
depression with drowsiness, decreased body temperature, bradycardia,
shock-like hypotension, apnoea and coma.
Store below 25°C. Protect from
light. Do not use 1 month after first opening. Keep out of reach of